Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-18

DEP® radiopharmaceuticals program advancing towards a clinical study Starpharma has made good progress this quarter in its DEP® radiopharmaceuticals program, both internally and with potential collaborators in this space.


This is almost word for word what we have heard for almost a decade about the DEP® drugs trialed by Starpharma but hey don't take my word for it, look through past Starpharma ASX announcements ? I guess things don't change when you leave the same Chairman in his position regardless of engaging a new CEO (IMO of course)


The fan club on here are now trying to skip over the failure to deliver any DEP® license deals in the last few years after phase 2 trial results were released and focus on the newest / latest and supposedly greatest Starpharma development DEP® radiopharmaceuticals ... you seriously can't make this stuff up


One final point that many have made - the new CEO is cutting back everything ... withdrawing regulatory submissions in both the USA and Australia for SPL7013 products .... deprioritising DEP® Docetaxel etc etc .... the only things that don't appear to be getting cut or decreased by the new CEO are staff levels or performance rights - absolute disgrace IMO given we have ended up down here in the penny stock category !!